329932-22-1

Basic information

• Product Name: methyl 3-nitro-5-(1-pyrrolidinylcarbonyl)benzoate
• Synonyms: methyl 3-nitro-5-(1-pyrrolidinylcarbonyl)benzoate;methyl 3-nitro-5-(pyrrolidin-1-ylcarbonyl)benzoate
• CAS NO: 329932-22-1
• Molecular Formula: C₁₃H₁₄N₂O₅
• Molecular Weight: 278.26066
• Mol File: 329932-22-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-nitro-5-(1-pyrrolidinylcarbonyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-nitro-5-(1-pyrrolidinylcarbonyl)benzoate(329932-22-1)
• EPA Substance Registry System: methyl 3-nitro-5-(1-pyrrolidinylcarbonyl)benzoate(329932-22-1)

Safety Data

• Hazardous Substances Data: 329932-22-1(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 1955-46-0 5-nitro-1,3-benzenedicarboxylic acid, monomethyl ester 

Downstream Products

• 1445788-42-0 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)-5-(pyrrolidine-1-carbonyl)benzoic acid 
• 1445791-81-0 3-amino-5-(pyrrolidine-1-carbonyl)benzoic acid methyl ester 
• 1539276-49-7 N-{(1S,2R)-1-benzyl-2-hydroxy-3-[1-(3-methoxyphenyl)-1-methylethylamino]propyl}-3-piperidin-1-yl-5-(pyrrolidine-1-carbonyl)benzamide 
• 1539276-73-7 3-piperidin-1-yl-5-(pyrrolidine-1-carbonyl)benzoic acid methyl ester 
• 1539276-75-9 3-piperidin-1-yl-5-(pyrrolidine-1-carbonyl)benzoic acid 
• 1445879-45-7 3-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4yl)amino)-5-(pyrrolidine-1-carbonyl)benzoic acid 

Relevant articles and documents

Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit

Antimalarial hit 1SR (TCMDC-134674) identified in a GlaxoSmithKline cell based screening campaign was evaluated for inhibitory activity against the digestive vacuole plasmepsins (Plm I, II, and IV). It was found to be a potent Plm IV inhibitor with no selectivity over Cathepsin D. A cocrystal structure of 1SR bound to Plm II was solved, providing structural insight for the design of more potent and selective analogues. Structure-guided optimization led to the identification of structurally simplified analogues 17 and 18 as low nanomolar inhibitors of both, plasmepsin Plm IV activity and P. falciparum growth in erythrocytes.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3; R4; and R5 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.